<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: It has repeatedly been reported that the thrombolytic tissue plasminogen activator (tPA) may aggravate ischemic injury after <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The underlying mechanisms, however, remain unknown </plain></SENT>
<SENT sid="2" pm="."><plain>We hypothesized that tPA induces an inhibition of endothelial NO synthase (eNOS) after focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> that is responsible for ischemic damage and may be restored by 3-hydroxy-3-methylglutaryl <z:chebi fb="3" ids="15346">coenzyme A</z:chebi> reductase inhibitors </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: We examined the effects of tPA, administered either alone or in combination with <z:chebi fb="0" ids="38545">rosuvastatin</z:chebi>, on ischemic injury, on eNOS expression, and cell signaling after 90 minutes of intraluminal middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: In <z:mp ids='MP_0002169'>wild-type</z:mp> mice, tPA delivered immediately after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> significantly increased <z:mpath ids='MPATH_124'>infarct</z:mpath> volume 24 hours after reperfusion </plain></SENT>
<SENT sid="5" pm="."><plain>Coadministration of <z:chebi fb="0" ids="38545">rosuvastatin</z:chebi> completely reversed the tPA-induced brain damage </plain></SENT>
<SENT sid="6" pm="."><plain>Western blots of ischemic brain lysates showed that tPA markedly diminished eNOS levels, increased extracellular regulated kinase (ERK)-2, and <z:mp ids='MP_0004876'>decreased MAP</z:mp> kinase/p38 activity </plain></SENT>
<SENT sid="7" pm="."><plain>Cotreatment with <z:chebi fb="0" ids="38545">rosuvastatin</z:chebi> prevented the decrease in eNOS, reduced ERK-1/-2 and normalized p38 levels </plain></SENT>
<SENT sid="8" pm="."><plain>To elucidate the role of eNOS in tPA-induced ischemic injury, we also evaluated tPA effects in eNOS knockout mice </plain></SENT>
<SENT sid="9" pm="."><plain>In eNOS knockout animals, tPA again significantly increased <z:mpath ids='MPATH_124'>infarct</z:mpath> size after transient focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: In a mouse model of focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>, tPA induces eNOS inhibition, ERK-2 activation, and p38 inhibition, possibly as part of a more complex signaling response exacerbating brain injury </plain></SENT>
<SENT sid="11" pm="."><plain>3-hydroxy-3-methylglutaryl <z:chebi fb="3" ids="15346">coenzyme A</z:chebi> reductase inhibition reverses the effects of tPA by a mechanism independent of eNOS </plain></SENT>
</text></document>